Immunovant (IMVT) reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.60.
The clinical-stage immunology company didn't report any revenue for the quarter ended Sept. 30, as expected by analysts surveyed by Capital IQ.
The company's shares were up more than 1% in recent premarket activity.
Price: 29.10, Change: -0.29, Percent Change: -0.99
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。